---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000057"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:49:39.688298+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibrx Q1 net loss $43.3M; cash $216.5M after $100M loan; data readouts expected in 2025

## Summary
- Net loss $43.3M ($2.80/share) vs $78.7M ($5.77/share) in Q1 2024.
- Cash $216.5M at March 31, 2025, up from $152.6M after $100M loan from Oxford Finance in Jan 2025.
- INBRX-109 registration-enabling Phase 2 data for chondrosarcoma expected Q3 2025; CRC cohort data also Q3 2025.
- INBRX-106 Phase 2/3 data for HNSCC with Keytruda expected Q4 2025; interim NSCLC data Q4 2025.
- R&D expenses fell to $36.9M from $63.9M due to spin-off of INBRX-101 program in Q2 2024.

## SEC filing metadata
- accession: 0002007919-25-000057
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/0002007919-25-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/inhibrx-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000057
- JSON: https://secwatch.observer/filing/0002007919-25-000057.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.